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Abstract 
Degree project, Programme in Medicine, Evaluation of treatment of axillary and palmar 
hyperhidrosis with botox injections, Sofia Munther, 2016, Gothenburg University, 
Gothenburg, Sweden.  
Key words: Axillary hyperhidrosis, palmar hyperhidrosis, botulinum toxin, evaluation of 
treatment. 
Introduction: Hyperhidrosis is a skin condition were patients sweat excessively. It affects 
3 % of the population and has a major impact on quality of life. Primary hyperhidrosis has a 
mostly unknown pathogenesis, but sympathetic overstimulation of sweat glands is a main 
cause. Sahlgrenska’s dermatology department started offering botulinum toxin (botox) 
injections in September 2013 after a Health Technology Assessment concluded that there was 
scientific evidence to support palmar and axillary treatment. Since then 179 unique patients 
have received injections but this far no evaluation has been made.  
Aim: To evaluate the hyperhidrosis treatment with botox in the clinic by examining life 
quality in the patients, duration of treatment effect, effectiveness of treatment and side-effects. 
Methods: The treatment form data was assembled in Microsoft Excel. Melior was used to 
search for any missing data. Analysis was performed with the help of the department 
statistician, who used the R-project statistics program.  
Results: Pre-treatment dermatology life quality index (DLQI) showed significant 
improvement (p < 0.0001) over time for all age groups and for both palmar and axillary 
treatment. Duration only increased significantly (p < 0.05) between treatment 1 and 2 for 
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palmar patients < 20 and 20-30 years. Effectiveness of treatment was significantly higher for 
axillary treatment (mean 8.6) compared to palmar (mean 8.1). Pain from treatment was best 
reduced with nerve block, though this caused most pain by administration. Ice did not 
significantly differ from being without anesthetics in terms of treatment pain reduction. Side-
effects were mostly unreported: 3 % of the appointments reported muscle weakness, 1 % 
fainting and 0.4 % increased general sweating. 
Conclusion: Treatment with botox injections improves quality of life in hyperhidrosis 
patients over time, and not only when treatment is in effect. 
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Introduction 
Sweat glands 
Sweat glands are apocrine, eccrine and apoeccrine. The eccrine glands are mainly responsible 
for normal sweating and help with thermoregulation and improving the grip on the palms and 
soles. Eccrine glands exist all over the skin, excluding lips, external ear canal, clitoris and 
labia minora. The amount and size of the glands vary between people and the region of the 
body, causing each person to sweat an individual amount, and different regions to have their 
own sweat rate. The eccrine glands are made of a secretory coil in dermis and subcutaneous 
tissue and a duct leading up to the epidermis, opening to the surface of the skin. Cell types in 
the secretory coil are (seen in a light microscope): dark cells, secretory cells (of tubular 
epithelium) and myoepithelial cells whose function is to support the gland and help with 
secreting the sweat. The duct has luminal cells and basal duct cells, the basal cells can pump 
sodium and take part in reabsorbing salts from the ductal lumen [1, 2].  
Composition of sweat 
The main components of sweat are NaCl (sodium chloride), K (potassium), H2CO3 
(bicarbonate), ammonia, lactate and urea. The sweat is isotonic when excreted from the gland 
cells, but after passing through the duct it becomes hypotonic due to reabsorption from the 
ductal cells (reabsorption cannot keep up with increased sweat rate). Depending on the rate of 
sweating the concentration of Na can increase up to 10 times. Some diseases such as cystic 
fibrosis (saltier sweat), Addisons (saltier sweat) and badly regulated diabetes (glucose in the 
sweat) can change the composition of sweat [1, 2]. Membrane protein pumps for water has 
also been found in both the secretory coil and in the duct, helping in transportation of water 
during the sweat production [3]. 
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Eccrine gland control 
The glands respond to signals from sympathetic nerves of non-myelinated c class type and the 
main transmitter signal is cholinergic. Triggers of the signal can be thermal, osmotic, mental, 
emotional or gustatory factors or a cyclic spontaneous type of sweating [4]. Mental stimuli 
cause sweating especially on the soles and the palms. The myoepithelial cells are mostly 
controlled by cholinergic signals from sympathetic nerves [1]. 
Hyperhidrosis  
Hyperhidrosis is a skin disorder that causes excessive sweating in relation to 
thermoregulation, activated by heat, stress and physical effort. It can be primary or secondary, 
general or focal. General affects most of the sweat producing areas of skin and focal means 
that smaller regions such as the axillae, the palms or the soles are affected [1, 5]. The primary 
disease is of mostly unknown pathogenesis, though overstimulation of the sympathetic 
nervous system is one main cause. Secondary hyperhidrosis needs to be ruled out when 
making the diagnosis as it can be caused by a number of serious illnesses such as infectious 
(e.g. tuberculosis, malaria, endocarditis), metabolic (e.g. diabetes, hyperthyroidism, 
phaeochromocytoma), neurological, drugs (e.g. fluoxetine), menopause and congestive heart 
failure [1]. 
The hyperhidrotic sweat gland, its duct and secretory coil have the same morphological 
picture as a normal sweat gland, but are much more active and can be several times larger due 
to over-activity [6].  
Patients’ onset of disease depends on the affected area, axillary often starting during puberty 
and palmar starting before 18 years [7]. 
 
8 
 
Prevalence   
The prevalence of hyperhidrosis is around 3% with males and females affected equally. An 
American survey from 2004 [8] found that approximately 2.9 % (2.9 % for males, 2.8 % for 
females) of the American population suffers from hyperhidrosis, and further that 50.8 % (1.4 
% of the population) of them has axillary hyperhidrosis.  
The survey wanted to find the number of affected individuals independently of whether they 
had gone to a doctor for a diagnosis. Only 38 % of the responders had brought up their 
problem of sweating to a health care professional (47.5 % of the females, 28.6 % of the 
males) suggesting that the need is much bigger than the patients who ask for help. About one 
third (32.4 %) in the same survey said that sweating was ‘barely tolerable or intolerable’ and 
that it interferes ‘frequently or always’ (representing 3 or 4 on HDSS) and 91.6 % said it 
interferes on some level in their life [8]. 
Genetic transmission 
Primary hyperhidrosis is inherited in a likely autosomal dominant manner, though with 
incomplete disease penetrance [9]. In a study of 49 patients 65 % had a family history, 
compared to 0 % in the control group. The prevalence of the disease allele was said to be 5 % 
in the population and that 1 or 2 copies are enough to give someone hyperhidrosis 25 % of the 
time. Healthy alleles only cause hyperhidrosis 1% of the time [10]. Another study found that  
37 % of hyperhidrosis patients had a family history compared to 9 % in the control group and 
that 40 % of axillary patients reported family history and 28 % of palmar patients [5]. 
Diagnosis 
When a patient asks for help with excessive sweating it is important to make sure it is not due 
to secondary hyperhidrosis, and most often an interview and a clinical examination are 
enough. The general questions should focus on: pattern of sweating, age of onset, impact on 
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daily life, family history and symptoms that point to a secondary cause. The clinical 
examination should focus on finding evidence of excessive sweating and any symptoms 
pointing to secondary cause. 
Primary focal hyperhidrosis should have affected the patient for at least 6 months at the point 
of diagnosis. It should have at least 2 out of 6 symptoms: ≥ 1 episode per week, symmetrical 
and or bilateral sweating, stopping during sleep, starting before 25 years, impairment on daily 
life and a family history of the disease [11]. 
Impact on daily life 
Hyperhidrosis can have a large impact on many aspects in patients’ lives, making them suffer 
socially and professionally and holding themselves back from doing what they want [5, 8].  
Feeling self-conscious or hesitant when shaking hands, feeling limited when being with 
family or friends or in intimate situations, selecting clothes that will not show sweat stains, 
spending a lot of time on hygiene, or damaging papers from sweaty hands are just the 
beginning of a long list of situations that patients say they are limited in due to their 
hyperhidrosis [8]. Some patients even avoid certain jobs or feel that they can’t do their job 
properly, which can have an even greater negative impact in the long run [5].  
Symptoms and limitations make that mental health is worse in hyperhidrosis patients 
compared to the normal population. Depression and anxiety is more common than in control 
groups [8]. One study showed that 63 % felt unhappy or depressed and that axillary patients 
reported this more often than palmar patients [5]. 
Hyperhidrosis disease severity scale (HDSS) 
The HDSS is a quick and easy tool to use for measuring the disease impact on a patient’s life 
(attachment 1). It has 4 score levels: score 1-2 represent mild or moderate hyperhidrosis, score 
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3-4 severe hyperhidrosis. The score is determined by asking the patient which statement out 
of 4 that fits their disease at the time. Statement 1 represents score 1 on HDSS: ‘my sweating 
is never noticeable and never interferes in my daily activities’. The same pattern returns in 
statement 2, 3 and 4, though the intensity increases. Statement 2: ‘… tolerable but sometimes 
interferes …’ Statement 3: ‘… barely tolerable and frequently interferes…’ Statement 4: ‘… 
intolerable and always interferes…’  
Each level correlates to the sweat production and a 1 point improvement has been shown as a 
50 % reduction of sweat and 2 points a 80 % reduction [12].  
Dermatology Life Quality Index (DLQI) 
This instrument of measurement of life quality in dermatology patients was created in 1993 
(Appendix A). To form the questionnaire 120 dermatology patients were asked to write down 
how their skin disease and the treatment of it affected them in their daily life. The answers 
became the basis for the DLQI’s 10 questions, such as how embarrassed/self-conscious the 
patient has felt during the last week because of their skin disorder, or if it has disturbed 
working, studying or leisure time etcetera. Each question can be answered with ‘very much’ 
(valued to 3 points), ‘a lot’ (2 points), ‘a little’ (1 point) and ‘not at all’ (0 points). Some 
questions also have a ‘not relevant‘ option (0 points). In total the score can reach maximum 
30 and minimum 0 points, the higher the score the greater the negative impact in the patient’s 
life [13]. The test showed high reliability and is now a common tool in dermatology studies 
and clinical work for evaluating treatments and it has been translated into 55 languages and 
used in 32 countries [5, 14]. 
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Treatment  
The first step of treatment, after proper diagnosing and informing the patient about the 
condition, is assessment of the area needed to be treated. In case of large or multiple areas a 
combination of treatments may be necessary [15, 16].  
Aluminum chloride is usually the first step and can be applied to any part of the skin. It can be 
bought over the counter in pharmacies, and comes in different strengths.  It should be applied 
to clean dry skin and in the case of the strongest type, used before bedtime and washed off in 
the morning. It can be reapplied on a weekly basis or daily if needed. Eczema and dry skin are 
common side-effects that are treated with a mild cortisone cream [12, 15-18]. 
Systemic treatment with oral anticholinergic is more useful in the case where large areas need 
treatment. In Sweden oxybutynin (an anticholinergic also known as Ditropan) is the most 
commonly used and treatment is started if aluminum chloride does not give satisfactory 
effect. The treatment unfortunately often causes side-effect to the extent that patients find it 
unbearable. Side-effects are dry mouth, constipation, urinary retention, and tachycardia [15-
18]. In a study with 19 patients 79 % (15 people) taking glycopyrrolate (an anticholinergic) 
had an effect on sweating, but 79 % also developed side-effects. One third had to stop because 
of their adverse effects and 21 % stopped the treatment when it was ineffective [19]. 
Iontophoresis is a method of sending an electrical current through a water bath, where hands 
or feet are placed. The current inhibits the sweat secretion and sometimes an anticholinergic 
agent is added to the water to increase this effect. The treatment takes about half an hour per 
use and needs to be repeated 4 times weekly [17, 18]. Side-effects are dry, irritated skin and 
pain. Because it is so time-consuming the treatment is not popular and not every clinic offers 
it, but the device can be purchased online [15, 16]. 
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Local surgery with removal of the sweat glands is in Sweden only used for axillary 
hyperhidrosis [15]. This can be done with e.g. suction curettage and excision. Excision has 
more complications such as excessive scarring and infection [17, 18]. Suction curettage has 
the risk of bleeding, hematoma, seratoma, infection, pain and scarring [20].   
Botox 
The botulinum toxin (BT) consists of a heavy amino acid chain and a light amino acid chain, 
combined with a disulfide bridge, which is what makes it biologically active. Injected BT 
binds to glycoproteins in the cholinergic nerve ending; the light chain is taken up by said 
nerve ending and starts cleaving the proteins that help transporting acetylcholine vesicles to 
the synaptic cleft. This hinders the synapse to signal and temporary sprouting of new synapses 
takes place until the synapse can regenerate. Because of regeneration the BT effect is not 
permanent, but dose and injection site can lead to different duration of effect. 
The molecule can travel along the nerve, but does not have any effect on the central nervous 
system due to the blood brain barrier and the slow speed (becomes inactive before reaching 
the central nervous system), side effects can instead come from systemic spread in the blood 
and local spreading of the botox to other nerve endings close to the injections sites that 
control muscles.  
The most common types of botulinum toxin used in health care are Botox, Dysport, 
Myobloc/Neurobloc and Xeomin [21]. Because of proteins in the preparation antibodies can 
be formed either against the BT or against the inactive complexing protein, possibly causing 
treatment failure if against the active toxin [21, 22]. 
Botox injections have in several studies proved to improve quality of life in palmar and 
axillary hyperhidrosis and for both adults and children [23-26]. Solish et al. looked at the 
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impact in life and quality of life after botox injections. They found that after treatment 
patients reported being more satisfied and being less limited at work and in personal 
relationships, feelings of being emotionally damaged lessened and patients needed less time 
for managing their hyperhidrosis. Life quality measured by Dermatology Life Quality Index 
also improved [7]. 
With botox being more common as a treatment, the length of time to study its effects has 
increased and some studies point towards that duration of treatment effect seems to have the 
potential of increasing over time with continuous treatments [27-29].  
Botox has in the treatment of hyperhidrosis shown to have mild to moderate side-effects [22, 
30] that resolves within weeks or a few months. Common side-effects are weakness in hands, 
or other muscle weakness, and pain or irritation in injection sites [30, 31].  
Health Technology Assessment 
At Sahlgrenska Dermatology Clinic a health technology assessment (HTA), led by Kristina 
Maltese, MD, and Madeleine Ryndel, MD, was published in March 2012. Its purpose was to 
assess the need of offering patients botox injections as treatment for axillary, palmar and 
compensatory hyperhidrosis (caused by sympathectomy). The search included botox type A 
and B and comparing its effects on quality of life, duration of treatment, sweat production,  to 
aluminum chloride, oral anticholinergic treatment, sweat gland curettage and placebo/no 
treatment. 
The assessment found that botox has better effect in axillary hyperhidrosis than placebo and 
aluminum chloride at improving quality of life and sweat production. Botox was also better 
than placebo in terms of duration of treatment effect. Botox was not found better than 
subcutaneous curettage at improving quality of life and duration of treatment effect (curettage 
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is considered a permanent solution) in axillary hyperhidrosis. Palmar treatment was found to 
have more increase in quality of life and more effect on the sweating with Botox compared to 
placebo. 
Most side effects were considered mild or moderate, with some patients with axillary 
hyperhidrosis getting compensatory sweating and almost half of patients with palmar 
hyperhidrosis getting passing muscle weakness after injections.  
The yearly cost of treatment for one patient was estimated to 8200 SEK [32]. 
Aim  
The aim was to evaluate the hyperhidrosis botox treatment at Sahlgrenska Dermatology 
Department, by examining DLQI, effectiveness, duration of treatment effect and side-effects. 
Also evaluation of the treatment form as a tool for gathering the patients’ information.  
Project plan research questions 
 How long is the duration of treatment effect, comparing axillary and palmar treatment 
or the combination of the two? 
 How big of an effect do the patients experience after the treatments? 
 How are the patients according to the Dermatology Life Quality Index (DLQI) score, 
after treatments, comparing axillary, palmar and the combined treatment? 
 How many patients have answered the DLQI-form?  
 Are the results in accord with current research on hyperhidrosis botox treatment?  
 How well does the clinic use the treatment form to follow their patients? 
 Is there a need for the clinic to improve its follow up and assessment of their patients 
who get botox injections?   
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Method 
A few months after the treatments started a form was constructed in Microsoft Excel 
(Microsoft Corporation, Washington, USA) to follow the patients’ response. This treatment 
form was the base of information for this evaluation.  
A list of patients who had visited the clinic was taken from the booking system ELVIS 
(Elektroniskt VårdInformationsSystem, Region of Västra Götaland, Sweden), an electronic 
patient booking system, and compared it to the treatment forms to make sure no patient was 
excluded in case a form was missing.  
The first patient to visit the clinic came at 3rd of September 2013 and all patients who received 
botox injections and had information about the treatment in the treatment form or in Melior 
(Siemens, Münich, Germany) until 2nd of September 2016 were included.  
The form included 13 points of interest:  
- The doctor or nurse who performed the treatment.  
- Date of treatment.  
- Hyperhidrosis Disease Severity Scale (1-4, 4 being the worst), at the time of treatment.  
- Treated area (either axillary, palmar, combined (both areas at same appointment) or mixed 
(both areas at separate appointments)).  
- Dose and type of botulinum toxin (Dysport or Botox).  
- Amount of dilution.  
- Choice of anesthetics: ice (ice in a plastic bag held against injection sites for 15 minutes 
before injections), nerve block (injected), Coolsense (a pen-like applicator with a frozen core), 
Emla (a lodicaine and prilocaine cream) or no anesthetics (often called ‘none’ in graphs and 
tables to save space).  
- Pain caused by anesthetics on VAS (0-10, 10 being the worst).  
- Pain during treatment, answered on VAS (0-10, 10 being the worst).  
- Effectiveness of treatment (0-10, 10 being the best), estimated by patient at following 
appointment. 
- Duration of treatment effect (answered in weeks or months), estimated by patient at following 
appointment.  
- Side-effects (none or description of side-effect as experienced by patient), answered at 
following appointment.  
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- Dermatology life quality index (DLQI), questionnaire answered at the same day as treatment 
(when no effect has set in, called pre-treatment) and 3 weeks post-treatment (when full effect 
has been reached). 
Melior was used to complement missing or lacking information. If Melior had information 
that did not correspond with the forms then the information in the forms was used and a 
comment was made in a commentary field in Excel. All data was collected in Excel. 
Ethics 
Permission to gather patient information from the treatment forms and Melior and to visit the 
clinic to observe the treatments was received from the head of the dermatology clinic Helena 
Gustafsson. 
Statistical methods 
The R Project for Statistical Computing version 3.0.3 (The R Foundation for Statistical 
Computing, Vienna, Austria) was used. I had the help of the statistician Martin Gillstedt in the 
department of dermatology for calculations and analysis.  
Pain:  
- Kruskal-Wallis test was used for comparing the different anesthetic options’ treatment pain 
and administration pain (separate test for axillary and palmar treatment).  
- Where significant change was found Pairwise Wilcoxon’s rank-sum test (also called 
Wilcoxon’s signed-rank test) was used to further look into each anesthetic compared to the 
other.  
Effectiveness: 
- Wilcoxon’s rank-sum test was used to compare genders in the axillary and palmar treatment 
and also used to compare axillary with palmar treatment.  
Duration of treatment effect: 
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- Wilcoxon’s rank-sum test was used on axillary and palmar treatment separately on whether 
the duration changed with more treatments. 
- Pairwise Wilcoxon’s rank-sum was used on each age group between treatment appointment 1 
and treatment 2.  
DLQI 
- Spearman correlation compared each age group, treatment area and gender with number of 
treatments to see if change happened over time.  
- Kruskal-Wallis was performed at first appointment for the treatment areas to find any 
difference in DLQI-score. 
Kruskal-Wallis: 
- Non parametric test to compare the samples in two groups. A significant test means that at 
least one sample differs from another. It does not tell which sample, but just compares the 
groups.  
Spearman correlation: 
- Non parametric test to assess the relationship between x and y, who do not have to have a 
linear relationship for Spearman to give significance.  
Wilcoxon’s rank-sum: 
- Non parametric test that compares a related sample or one sample with many measurements.  
- Wilcoxon’s signed-rank test: similar but comparing a sample’s value over time with other 
similar samples, it is a test meant for paired data. 
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Results  
The patients 
Since the start (3/9 2013 - 2/9 2016) 179 unique patients have received treatment. Of these 60 
% were women and 40 % men, with similar ages at 1st appointment. Females had the mean 
age 26.6 years and males the mean 28 years. The oldest person at their first appointment was 
72 years and the youngest 14 years. Most patients were between 20-30 years (45 %). The 
patient groups < 20 years (28 %) and > 30 years (27 %) were of similar size, though the older 
had a much wider age span. 
Treatment area 
About half of the patients (48 %) received only axillary treatment and 37 % only palmar. 
Fewest were the 5 % in the combined treatment group and the mixed group at 10 %. 
Hyperhidrosis disease severity scale (HDSS) 
The HDSS had most data from the patients’ first appointment with 77 % answered. 
Appointment 4-8 only had 1 HDSS-entry. There were too few data to see any significant 
lowering of the mean, but appointment 2 - 3 seems to be going in the right direction (table 1).  
Men and women have at the 1st appointment similar means; females 3.57 (95 % CI 3.45-3.69) 
and males 3.64 (95 % CI 3.50-3.78). 
 Table 1 – HDSS scores for all hyperhidrosis patients at 
appointments 1-3 
  Median Mean n Na's 
Appointment no. 1 4 3.60 137 42 
Appointment no. 2 3 3.33 15 110 
Appointment no. 3 2 2.33 3 85 
Appointment numbers (no.) 4-8 only had 1 reply out of the total  
102 appointments and therefore excluded. There was too few HDSS data to calculate 
significance in score changes.             
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The treatment 
Treatment appointments 
The number of visits the patients did to the clinic was minimum 1 and maximum 8 times. 
Most patients returned only maximum 2 times (table 2): median 2 and mean 2.77 (95 % CI 
2.51-3.02).  
Table 2 - Patients’ maximum botox treatment appointments at the clinic 
 
  1 Appoint. 2 Appoint. 3 Appoint. 4 Appoint. 5 Appoint. 6 Appoint. 7 Appoint. 8 Appoint. 
No. of unique 
patients 53 38 38 25 9 8 5 3   
Proportion 30% 21% 21% 14% 5% 4% 3% 2%   
51% of patients came only for 2 treatment appointments. Only 3 patients came back 8 times for treatment.  
 
Pain from treatments 
In the beginning the clinic offered 4 types of anesthetics; Coolsense, Emla, ice and nerve 
block, but ice and nerve block were the most commonly offered and used (table 3).  
Table 3 - Number of times 
anesthetics were used for 
palmar and axillary botox 
treatments 
  
Palmar 
patients 
Axillary 
patients 
Coolsense 5   0   
Emla 4   17   
No anesthetic 17   202   
Ice 145   10   
Nerve block 55   0   
Total 226   229   
 
Axillary treatment pain 
All axillary treatments were included in these calculations, including patients with the 
combined and mixed treatments. 
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There was no significant difference between the three choices (Kruskal-Wallis p = 0.21) 
(figure 1A).  
Emla-cream was not common (7 %) and had the VAS score mean of 4.03  (95 % CI 2.55-
5.52). Ice was also uncommon (4 %) with the mean 5.40  (95 % CI 4.22-6.58). Most common 
was not using anesthetics (88 %) with the mean 5.06 (95 % CI 4.76 – 5.36). 
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No significant difference (p = 0.21) in VAS  score could 
be found, with Kruskal Wallis test, between the 
different anesthetic options for axillary treatment. 
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p < 0.0001
 
p = 0.0007 
p = 0.011 
Figure 1- Pain measured on VAS caused by botox injections after administration of patients’ choice of 
anesthetics 
p = 0.21 
With the Kruskal Wallis test nerve block had a significantly 
lower VAS than ice, no anesthetics and Emla. Coolsense 
had too few data to calculate significance. No significant 
difference was found between the VAS scores for ice, no 
anesthetics and Emla.                    
B - Palmar treatment 
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Palmar treatment pain 
All palmar treatments were included in these calculations, inlcluding patients in the combined 
and mixed treatments. 
There was no significant difference (Pair wise Wilcoxon’s rank-sum test p > 0.05) between 
Coolsense, Emla and ice compared to no anesthetics (figure 1B). 
Coolsense was uncommon (2 %) with the mean 5.8 (95 % CI 3.11-8.49). Emla, also 
uncommon (2 %), had the mean 7.67 (95 % CI 6.23-9.10). Ice was used the most (64 %) and 
had the mean 5.96 (95 % CI 5.64-6.29).  
Nerve block (used 24 %) had the significantly lowest score compared to ice, no anesthetics 
and Emla. Nerve block had the mean 3.33 (95 % CI 2.52-4.14) (figure 1B). 
Not using any pain relief had the mean 6.35 (95 % CI 5.29-7.40). 
Pain caused by administrating anesthetics 
For the axillary treatment there was no significant difference between ice and Emla (Kruskal-
Wallis p = 1.00). Emla and ice both had the mean 0.  
For palmar treatment nerve block was significantly more painful than all other choices using  
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The nerve block administration pain was significantly higher than all other anesthetics, 
using Pairwise Wilcoxons ranksum test. Coolsense and Emla caused no pain during 
administration. 
Figure 2 - Pain measured on VAS caused by palmar anesthetics   
p < 0.0001 
p = 0.018 
p = 0.001 
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Pairwise Wilcoxon’s rank-sum test: ice (p=0.0001), Emla (p=0.018), Coolsense (p=0.001) 
(figure 2). Ice had the mean 0.3 (95 % CI 0.1-0.6) and nerve block had the mean 5.1 (95 % CI 
4.4-5.8). Emla and Coolsense both had the mean 0. 
Duration of treatment effect 
Treatment areas 
Axillary had longer duration than palmar. Palmar had the mean 112.2 days (95 % CI 102.9-
121.6) and axillary the mean 126 days (95 % CI 117.3-135.0).  
Neither palmar nor axillary had an increase in duration correlating to more treatments (figures 
3A and 3B). Palmar treatments 3-7 had few patients and as seen wide confidence intervals. 
 
 
 
 
 
1st and 2nd appointmentand 
There is a visible increase in duration between appointment 1 and 2 (figures 3A and 3B).  
Pairwise Wilcoxon’s rank-sum test found significant increase for the palmar patients <20 
years and 20-30 years old (table 4B). For palmar patients >30 years olds no significant change 
could be found. 
None of the axillary patients in either age group had an increase in duration (table 4A).  
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Figure 3 –Duration of botox treatment effect for each treatment appointment 
p = 0.8 p = 0.7 
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1st and 2nd appointment 
There is a visible increase in duration between appointment 1 and 2 (figure 3B). 
Pairwise Wilcoxon’s rank-sum test found significant increase for the palmar patients < 20 
years old (p = 0.026) and 20-30 years old (p = 0.014) (figure 4). For the palmar patients > 30 
years old no significant change could be found.  
None of the axillary patients in either age group had an increase in duration (figure 4).  
 
Figure 4 – Duration of botox treatment effect after 1st and 2nd treatment appointment 
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Only palmar patients < 20 years old (p = 0.026) and 20-30 years old 
(p = 0.014) had a significant increase in duration of treatment effect 
between their 1st and 2nd appointment using the Pairwise 
Wilcoxon's rank-sum test.  
palmar treatment 1 palmar treatment 2
axillary treatment 1 axillary treatment 2
p = 0.026 p = 0.014 
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Effectiveness of treatment 
The estimated effectiveness of the injections was higher in the axillary group than palmar 
(Wilcoxon’s rank-sum p = 0.006). Axillary patients had the mean 8.6 (95 % CI 8.2-8.9) and 
palmar patients the mean 8.1 (95 % CI 7.7-8.5) (figure 5). 
The axillary patients > 30 years had significantly higher score than 20-30 years (Pairwise 
Wilcoxon’s p = 0.003). 20-30 years had the mean 7.9 (95 % CI 7.3 - 8.6) and > 30 years had 
the mean 9.3 (95 % CI 8.9 - 9.7). 
The palmar age groups had no significant difference (Kruskal-Wallis p = 0.75).  
Patients with only one area of treatment had no significant difference to those with the 
combined treatment (Kruskal-Wallis test p > 0.05).  
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         Areas of treatment 
Wilcoxon's rank sum test showed a significant difference between 
axillary and palmar patients' self-estimated effectiveness of 
treatment (p = 0.006) on VAS. 
p = 0.006 
Figure 5 - Effectiveness of botox treatment measured on VAS for 
axillary and palmar patients 
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Dermatology Life Quality Index (DLQI) 
Patients had an increased life quality with more treatments; they were less limited in their 
daily life by their condition, and this even when they had the least effect from the treatment. 
At the 1st appointment some patients had never been treated with botulinum toxin before, 
while others might have had the disease for years and gotten treatments at other clinics.  
DLQI pre-treatment for all patients had a significant decrease with more treatments 
(Spearman correlation: p < 0.0001).  
At 1st appointment the mean was 12.8 (95 % CI 11.2- 14.4). The 8th appointment had the 
mean 2 (CI not available because of lack of data) (figure 6A).  
All age groups, axillary and palmar patients had a significant decrease of pre-treatment DLQI 
with more treatments when using the Spearman correlation p < 0.005. 
There was no significant difference in DLQI between the different treatment areas (Kruskal-
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DLQI pre-treatment (at peak of disease symptoms) showed 
a significant difference with more treatment appointments 
(p < 0.0001, Spearman correlation test). 
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                  Treatment appointments 
DLQI post-treatment (at peak of treatment effect) did 
not significantly change with more treatments (p=0.27, 
Spearman correlation test.  
B - DLQI 3 weeks post-treatment    
Figure 6 – DLQI for hyperhidrosis patients at treatment appointments 1-8 
p < 0.0001 p = 0.27 
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Wallis p = 0.75).  
 There was no significant difference in the post-treatment DLQI with more appointments 
(Spearman correlation: p = 0.27). Patients reached the same level of life quality post-
treatment after several appointments.    
DLQI for all patients after 1st appointment (post-treatment) had the mean 3.3 (95 % CI 2.2-
4.4). Appointment 8 had the mean 2, but this was based on only 1 reply (figure 6B).  
Side-effects 
Pain was an anticipated occurrence during treatment and was not accounted for here. Of the 
495 treatment appointments few reported side-effects but also only 24 actual reports of no 
side-effects (4.8 % of the treatment appointments) and most treatment forms were blank in 
this section.  
The most common side-effect was muscle weakness, reported 15 times (3.0 %): 14 (2.8 %) 
included weakness in the thumb and index-finger grip, 3 (0.6 %) had general weakness in the 
hands and 1 (0.2 %) had weakness in the distal part of the arms, hands and fingers. The 
weakness always receded within weeks; the longest period was 6 weeks. 
Irritation around the injections sites such as pain, itching and or bruising was reported 6 times 
(1.2 %).  
5 patients (1.0 %) fainted during or shortly after the injections, most assumed to be a reaction 
to the pain of the treatment. 4 of these 5 were < 20 years old and 1 was 23 years. 4 of the 5 
had used ice as pain relief, 1 had no reported use of pain relief.  
2 patients (0.4 %) reported increased general sweating. 
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Missing data 
Throughout the treatment form there were many boxes left empty. HDSS was missing 68 %: 
1st appointment had 77 %, 4th-8th only 1 entry in total. DLQI pre-treatment was missing 54 % 
and post-treatment missed 55 %. Effectiveness was missing 45 % and duration was missing 
40 %.  Side-effects lacked most data: 88.3 % were empty boxes.  
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Discussion  
Life quality 
The quality of life pre-treatment improved over time. That it was measured before the renewal 
dose means that patients feel better even at their worst, which is a good sign. That fact that the 
mean post-treatment DLQI does not reach 0 point shows that there still is a lingering 
disturbance from the hyperhidrosis even with treatment at full effect, and also that patients are 
never problem free.  
The HDSS was not answered in enough extent to see significant change over time, and makes 
it hard to compare to other studies. The median and mean did lower from appointment 1 to 2 
and 3, which hints that it was going in the right direction. Improvement on the HDSS can be 
translated to reduction of sweat [12] and as patients have rated their treatments > 8 on 10 for 
effectiveness they likely would have rated lower on HDSS too if asked, since it has done so in 
other studies [12, 33].  
Perhaps if the treatment is given enough time it will improve patients to that degree that they 
are no longer aware of their condition, both physically and mentally. In a study from 
Stockholm where 84 patients were treated with Xeomin and Neurobloc, axillary patients went 
from mean DLQI score of 12.0 pre-treatment to 1.7 3 weeks post-treatment and the palmar 
patients from 10.3 to 1.2. 45 % of axillary patients and 43 % of palmar patients had reached 0 
on DLQI [25], so it is possible to be completely without problems from the disease with the 
right treatment. There was no information on the level of problem these patients had before 
the treatment. 
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Duration of treatment effect 
The duration did not increase except for the younger patients in the palmar group between 
appointment 1 and 2. Treatments 3 -8 for axillary and palmar patients did not have enough 
patients or data to make proper conclusions. In two studies by Lecouflet et al. with palmar and 
axillary patients during 11 years the duration increased by 3 months for axillary patients and 
2.5 for palmar [27, 28]. The current duration 112 days (3.7 months) for palmar and 126 days 
(4.2 months) for axillary is similar to what others have reported [30]. Perhaps the change the 
clinic made from Botox to Dysport during the 3 years also is preventing a visible increase in 
duration (though one study did not find significant difference in duration between Botox and 
Dysport [34]). Or is it as simple as needing more time to see an increase in duration. The 
duration increase in Lecouflet’s study had 11 years to build and also treated only with Dysport 
so maybe in a few years we will see the difference, but more data would be beneficial for 
analysis as well.  
Pain 
The treatment is quite painful and even the anesthetic administration is (though clearly nerve 
block stands out). It is interesting to see that ice remains the most popular, though patients 
with multiple appointments should have noticed that it is not of much help. Is ice useful as 
more than being a pain relief? Could it be that the stress of needles and a painful procedure is 
helped by feeling that they are doing something?  
What is also interesting is that other clinics seem to have a varied approach to the pain. 
Axillary studies mostly offer nothing for the pain [25, 31], sometimes Emla [25], and one 
study reporting only mild pain with no anethetics [35].  Palmar vary between ice from 5-10 
seconds [33] to 15 min [36] , to nerve block, one study complementing nerve block in case of 
incomplete effect with ice [37], to inhalation of a mixture of oxygen and nitrogen, or 
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hypoanalgesia (not specified) [28]. A study of 46 palmar patients mentioned the difference in 
perceived pain if nerve block did not take fully. The partial block happened to 17 % of whom 
75 % felt mild pain and 25 % moderate pain, compared to no pain for the patients who had 
successful pain nerve block [37]. Though the patients in this evaluation estimated their pain 
on VAS and thus not straight away translatable to mild or moderate, the mean 3.3 (95 % 2.52-
4.14) at least points out that most patients did not reach complete pain relief. Could this be 
because of clinicians’ technique of injection? 
Nerve block makes a significant difference in pain, but it is also very painful. Are a few 
minutes of VAS 5 when getting nerve block injections worth 10-15 minutes of VAS 3 during 
the treatment? Who are the patients who choose either anesthetic?   
Perhaps patients get better at handling the treatments over time and therefore notice the pain 
less? Recently there has been an improvement in how the ice is administrated at the clinic and 
patients have responded positively. In the beginning ice was administered with an ice block 
that did not cover the palm very well, now ice in a bag that better fits the hands is used 
instead. Future evaluation will tell if this has given a change in the treatment pain.  
Patients and appointments 
According to the American survey [8] there is little difference in female to male ratio, but big 
difference in how they ask for help. More females than males have received the treatment and 
this is the case in several other studies too[33]. Skin conditions cause a lot of emotional 
pressure on patients. Perhaps patients more prone to acknowledging their emotions and 
emotional disturbances will look for treatment and help more often that those who perhaps 
because of society’s expectations and norms are less in tune with their own emotions. The 
treatment has been offered for over 3 years, with up to 2 axillary and 3 palmar treatments 
offered yearly per patient. For some reason 51 % of patients have not shown up for more than 
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1-2 treatments, which is surprising as most also have a HDSS of median 4 and mean 3.6 at 1st 
appointment and should have reason to keep at the treatment.  
Why do patient not ask for help and why do patients drop out? Are they not informed enough 
to understand their disease and their options?  Hyperhidrosis is not a well-known disease and 
if more patients were reached with proper information maybe they would understand their 
condition and how the treatment works better, making them participants instead of passive 
receivers of the treatment. If it is the pain that makes them quit, making sure patients 
understand that nerve block is the best option, or perhaps combining anesthetic options for 
best result, could it be a solution? Asking, perhaps by a follow-up phone call, why patients 
drop out would be one way to get necessary information on how to improve the treatment of 
hyperhidrosis. 
Side-effects 
No side effects were serious, but 16 times (3 % of all appointments) muscle weakness was 
reported, though it was only 5 % that actually had a reported side effect. While I was 
registering the data it was unfortunately not possible to tell if an empty box was left empty on 
purpose or if it was forgotten, as many boxes were empty in many fields and columns.  Other 
reports have also mentioned muscle weakness and thumb-finger grip weakening, some with a 
higher frequency of side effects and some with less [26, 31, 32]. Technique of injection might 
be an important factor in this. 
Treatment forms 
There are a lot of different types of answers, and a lot of empty boxes. This makes it hard to 
compare results and draw conclusions as so much is missing. DLQI, duration of treatment 
effect and pain had enough to find significant differences, but side-effects and HDSS who are 
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both important to patients’ satisfaction with the treatment did not have enough data for 
comparisons. With limited time during appointments it is understandable that quick fixes 
sometimes are made. A new form might make the data gathering easier and quicker. A form 
in the computer system with shared access for clinicians, with clearer instructions (e.g. how to 
show in the form that no data was gathered) and less options (such as in the pain relief box; 
instead of 4 options where not all are used, maybe only 2 options) or quick answers, like a 
check box, would maybe help the efficiency of the filling out the form. If one just needs to 
check the boxes then perhaps even patients could be allowed to fill out some answers 
themselves, saving time for the clinicians and keeping the patients in the loop of how they are 
affected by the treatment. 
Conclusion 
This evaluation showed that treatment with botox injections improves quality of life in the 
clinic’s hyperhidrosis patients over time, and not only when treatment is in effect. Contrary to 
previous studies the duration of treatment effect did not increase for unknown reasons. Pain 
was best suppressed with nerve block, but it caused the most pain in its administration. It 
would be interesting to ask patients why they drop out or end the botox treatment, this could 
give important information that the clinic could use to improve the treatment of hyperhidrosis 
patients.  
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Populärvetenskaplig sammanfattning  
Behandling av överdrivna svettningar i armhålor och händer med botoxinjektioner 
Hyperhidros är en hudsjukdom där man har överdrivna svettningar.  Hyperhidros drabbar ca 3 
% av befolkningen. Sjukdomen kan ha sociala och professionella konsekvenser eftersom 
svettfläckar och rinnande svett kan påverka hur omgivningen bemöter de drabbade.  
Botox är förkortning för nervgiftet botulinum toxin som när det injicerats i huden förstör 
nervändarna till svettkörtlarna, vilket minskar de aktiverande signalerna och får patienter att 
svettas mindre. Nervändarna förnyas dock efter ett tag varför patienter måste få injektioner 
regelbundet.  
Sedan hösten 2013 har Sahlgrenska ebjudit patienter med hyperhidros botoxinjektioner. 
Denna utvärdering är den första sedan starten och görs med hjälp av att sammanställa datan 
från 179 unika patienters behandlingsformulär och patientjournaler. Målet är att utvärdera 
resultatet av behandlingen och hur bra formuläret är på att samla patientinformation. 
Dermatology Life Quality Index (DLQI) är ett frågeformulär som mäter livskvalitet hos 
hudpatienter. Vid varje förnyad behandling och 3 veckor efter behandlingen fick patienterna  
fylla i DLQI. Klinikens patienter fick bättre livskvalitet efter några behandlingar även innan 
de fått en påfyllnadsbehandling, alltså kunde patienerna leva mer ostört från hyperhidrosen. 
Injektionerna gör ont och patienterna fick skatta smärtan på en skala från 0-10 (10 var värst). 
Händerna gjorde mest ont på medelvärdet 6 medan armhålor skattades med medelvärde 5. 
Armhålorna fick oftast ingen bedövning men handpatienterna fick välja mellan nervblockad 
och is. Is gav inte någon skillnad jämfört med att vara utan bedövning, men nervblockad hade 
bra effekt (smärtan hade medelvärde 3). Problemet med nervblockad är att det också gör ont 
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att injicera (medelvärde 5) och patienterna inte kan använda sina händer när de är 
bortdomnade under några timmar.  
Hur länge effekten sitter i av botoxinjektionerna har i några studier visat sig öka med 
upprepade behandlingar. Hudklinikens patienter hade inte någon ökad duration av 
behandlingseffekten, förutom mellan 1:a och 2:a behandlingen för de med handhyperhidros 
som var under 30 år.  
Patienterna tycker att effekten av botoxinjektioner är hög. De fick skatta den på en skala från 
0-10 (10 var bäst) och tyckte att handbehandlingen var 8.1 och armhålebehandlingen var lite 
bättre på 8.6.   
Den vanligaste biverkan, som rapporterades vid 3% av alla besök, var muskelsvaghet. 
Muskelsvaghet kan ske om botoxet sprider sig till nervändarna som går till muskler i 
injektionsområdet. Särskilt handpatienterna kan ha det besvärligt, oftast med att greppa 
mellan tumme och pekfinger, men alla klinikens patienter blev bättre inom några veckor.  
Sammanfattningsvis får patienterna bättre livskvalitet efter upprepade botoxbehandlingar och 
de tycker att effekten är bra, men hur länge effekten satt i ökade inte med tiden. Patienterna 
föredrog is framför nervblockad, trots att nervblockad var bästa bedövningen, men den gjorde 
ondast att få.  
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